Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246571 · ClinicalTrials.gov registry record · Phase 2
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
NCT00246571 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 217 participants.
The verdict
NCT00246571, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
Study Summary
The purpose of this study is to compare progression free survival for SU011248 \[sutent (sunitinib malate)\] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast cancer.
Interventions
- DRUG Chemotherapy
- DRUG SU011248
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2006-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246571
The ClinicalTrials.gov registry entry for NCT00246571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT00246571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246571 about?
NCT00246571 is a clinical study titled "Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer". The purpose of this study is to compare progression free survival for SU011248 \[sutent (sunitinib malate)\] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast cancer.
What is the current status of trial NCT00246571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2006-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00246571?
The interventions under investigation include: Chemotherapy (DRUG), SU011248 (DRUG).
Who is sponsoring clinical trial NCT00246571?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.